TABLE 2.

Breakthrough infections in the tixagevimab/cilgavimab group

#	Date of infection	Most common variant at the timea	SOT	Number of vaccines	Months since last vaccine	T/C dose (mg)	Days since T/C	Hosp.	Treatment	Outcome
1	Jan. 19th 2022	B.1.1.529	Kidney	4	3.9	150–150	7	No	None	Recovered
2	Feb. 5th 2022	B.1.1.529	Lung	3	0.9	150–150	8	Yes	Remdesivir	Recovered
3	March 2nd 2022	B.1.1.529	Lung	4	1.1	150–150	19	No	Bamlanivimab	Recovered
4	March 29th 2022	BA.2	Liver	3	7.4	150–150	46	No	Bebtelovimab	Recovered
5	April 13th 2022	BA.2	Lung	2	6.1	150–150	91	No	Bebtelovimab	Recovered
6	April 21st 2022	BA.2	Lung	3	8.1	150–150	99	No	Bebtelovimab	Recovered
7	April 24th 2022	BA.2	Kidney	4	2.2	300–300	11	No	Bebtelovimab	Recovered
8	May 6th 2022	BA.2	Lung	3	8.5	150–150	114	No	MAB at outside institution	Recovered
9	May 15th 2022	BA.2	Lung	4	9.0	150–150	95	No	MAB at outside institution	Recovered
10	May 15th 2022	BA.2	Kidney	4	3.4	150–150	81	No	Bebtelovimab	Recovered
11	May 30th 2022	BA.2.12.1	Kidney	3	9.5	150–150	102	No	Bebtelovimab	Recovered

Abbreviations: MAB, monoclonal antibody; SOT, solid organ transplant; T/C, Tixagevimab/cilgavimab.

^aBased on the most prevalent SARS-CoV-2 variant in region 1 (including Massachusetts) from the Center for Disease Control and Prevention COVID data tracker: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.